Literature DB >> 2862516

Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B.

S W Schalm, R A Heytink, H R van Buuren, R A de Man.   

Abstract

Patients with chronic hepatitis B with active viral replication had a significantly greater fall in DNA polymerase and hepatitis-Be antigen when treated with interferon and acyclovir together than when treated with either interferon or acyclovir alone. Apart from fatigue and thrombophlebitis, tolerance of the combination therapy was excellent. The combination therapy appears the most promising for conversion of a state of active viral replication into virus latency.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2862516     DOI： 10.1016/s0140-6736(85)92498-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

Authors:  K L Hartshorn; M W Vogt; T C Chou; R S Blumberg; R Byington; R T Schooley; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 3.  Historical treatment of chronic hepatitis B and chronic hepatitis C.

Authors:  P Ferenci
Journal:  Gut       Date:  1993       Impact factor: 23.059

4.  Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol.

Authors:  K Kanai; S Morioka; T Nakajima; H Ishii; K Tamakoshi; H Matsuda; M Matsumoto; N Mizushima; Y Takehira
Journal:  Gastroenterol Jpn       Date:  1988-02

5.  Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the pre-S/S and pre-C/C genes during chronic HBV infection.

Authors:  A Tran; D Kremsdorf; F Capel; C Housset; C Dauguet; M A Petit; C Brechot
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Trial of (+)-cyanidanol-3 in patients with hepatitis B chronic liver disease.

Authors:  P W Keeling; L Viola; M G Anderson; J H Marigold; J C Macartney; F J Paradinas; I M Murray-Lyon; R P Thompson
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344

7.  Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B.

Authors:  J Hayashi; W Kajiyama; A Noguchi; K Nakashima; M Hirata; S Hayashi; S Kashiwagi
Journal:  Gastroenterol Jpn       Date:  1991-12

8.  Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.

Authors:  H L Janssen; L Berk; S W Schalm; R A Heijtink; G Hess; S Rossol; K H Meyer zum Buschenfelde; R A Chamuleau; P L Jansen; H W Reesink
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 9.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Effects of acyclovir and vidarabin 5'-monophosphate on anti-duck hepatitis B virus in an in vitro culture system.

Authors:  K Motegi
Journal:  J Gastroenterol       Date:  1995-04       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.